What is the recommended enoxaparin dose based on a patient's weight for therapeutic anticoagulation and prophylaxis?

Enoxaparin Weight-Based Dosing

For therapeutic anticoagulation, use enoxaparin 1 mg/kg subcutaneously every 12 hours, and for prophylaxis, use 40 mg subcutaneously once daily in normal-weight patients, with critical dose adjustments required for renal impairment, obesity, and low body weight.

Therapeutic Anticoagulation Dosing

Standard Dosing (Normal Weight)

• 1 mg/kg subcutaneously every 12 hours OR 1.5 mg/kg once daily 1, 2
• For acute coronary syndromes: 1 mg/kg subcutaneously every 12 hours 3, 2
• Maximum dose for first 2 doses in elderly with fibrinolytic therapy: 100 mg (age <75 years) or 75 mg (age ≥75 years) 3, 2

Renal Impairment Adjustments

Critical adjustment required for CrCl <30 mL/min:

• Reduce to 1 mg/kg subcutaneously every 24 hours (once daily) 3, 4, 2, 5
• This is the only LMWH with FDA-approved renal dosing 4, 5
• For moderate renal impairment (CrCl 30-60 mL/min), some evidence supports dose reduction, though not universally required 4, 5

Obesity Dosing (BMI ≥30 or Weight >100 kg)

Reduce weight-based dosing in severe obesity:

• For weight >150 kg: Consider 0.65-0.92 mg/kg rather than standard 1 mg/kg 6
• Standard 1 mg/kg dosing in patients >150 kg increases bleeding risk 2.4-fold without improved efficacy 6
• Target anti-Xa levels: 0.5-1.0 IU/mL measured 4 hours post-dose 7
• Doses ≥0.95 mg/kg in obesity are associated with 85% of bleeding events 7
• Optimal therapeutic range in obesity: 0.75-0.85 mg/kg achieves therapeutic anti-Xa in 66% of patients versus only 42% with standard dosing 7

Low Body Weight (<50-57 kg)

• Standard dosing appears safe in underweight patients 8, 9
• No dose reduction required for therapeutic anticoagulation unless weight <50 kg, then consider monitoring anti-Xa levels 1

---

Prophylactic Dosing

Standard Prophylaxis (Normal Weight)

• 40 mg subcutaneously once daily 1, 10
• For hospitalized medical patients, surgical patients, and cancer patients 1

Renal Impairment

• 30 mg subcutaneously once daily if CrCl <30 mL/min 4, 10

Obesity Prophylaxis (BMI ≥40 or Weight >100 kg)

Higher dosing required for adequate prophylaxis:

• 40 mg subcutaneously twice daily for patients >130-160 kg 11, 12
• Alternative: 0.5 mg/kg once daily 11
• Standard 40 mg once daily results in subtherapeutic anti-Xa levels in 41-59% of obese patients 12
• Target prophylactic anti-Xa: 0.2-0.4 IU/mL 12

Post-Bariatric Surgery

• 40 mg once daily is adequate - higher doses (60 mg) do not reduce VTE but increase supra-prophylactic anti-Xa levels 13
• No difference in VTE, bleeding, or mortality between 40 mg and 60 mg dosing 13

Low Body Weight (<57 kg or BMI <18.5)

• 30 mg subcutaneously once daily for prophylaxis 8, 9
• Reduces bleeding risk without increasing VTE compared to standard 40 mg dose 8, 9
• Major bleeding rate: 0.8% with 30 mg versus 1.5% with 40 mg 9

Trauma Patients

Weight-based prophylaxis superior to fixed dosing:

• 0.5 mg/kg subcutaneously twice daily (range 0.43-0.54 mg/kg) 14, 15
• Standard 30 mg twice daily results in subtherapeutic levels in 33-92% of trauma patients 14
• Weight-based dosing achieves therapeutic trough anti-Xa (≥0.1 IU/mL) in 61% versus only 8% with standard dosing 15

---

Critical Dosing Caveats

Monitoring Requirements

• Anti-Xa monitoring NOT routinely required except in:
  • Obesity class ≥2 (BMI ≥35) 11, 7
  • Renal impairment (CrCl <50 mL/min) 4, 5
  • Pregnancy
  • Extremes of weight (<50 kg or >150 kg) 4, 5
• Measure anti-Xa 4 hours post-dose after 3-4 doses for steady state 5

Perioperative Management

• Bridging dose: 1 mg/kg subcutaneously twice daily or 1.5 mg/kg once daily 16
• Last pre-procedure dose: Half the total daily dose given morning of day before procedure 16
• Resume 24 hours after low-moderate bleeding risk procedures, 48-72 hours after high-bleeding risk procedures 16

Pediatric Obesity

• Lower doses required: Mean 0.8 mg/kg twice daily achieves therapeutic levels 17
• Children with BMI 95th-99th percentile need 0.95 mg/kg twice daily 17
• Children with BMI >99th percentile or weight >100 kg need only 0.7-0.75 mg/kg twice daily 17
• Weight shows strongest negative correlation with dose requirement 17

Common Pitfalls

1. Do not use standard 1 mg/kg dosing in patients >150 kg - increases bleeding without benefit 6
2. Do not use 40 mg once daily prophylaxis in trauma patients - 92% have subtherapeutic levels 14
3. Do not forget renal dose adjustment - enoxaparin accumulates with CrCl <30 mL/min 4, 10, 5
4. Do not use standard prophylaxis in severe obesity - 40 mg twice daily or weight-based dosing required 11, 12
5. Reduce dose in underweight patients (<57 kg) for prophylaxis to 30 mg daily to minimize bleeding 8, 9